Participant flow

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer · Source last updated 2014-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Cetuximab loading dose of 400 milligrams/square meter (mg/m²) administered intravenously on Day 1 of Cycle 1; subsequently 250 mg/m² intravenously weekly. Pemetrexed 500 mg/m² administered intravenously on Day 1 of every 21-day cycle, 1 hour after cetuximab. Carboplatin area under curve (AUC) 5 or cisplatin 75 mg/m² administered intravenously on Day 1 of every 21-day cycle, 30 minutes after pemetrexed. Maximum 6 cycles. Participants who did not experience disease progression after 6 cycles continued on cetuximab (250 mg/m² intravenously weekly) monotherapy until disease progression.

   id

   FG000

   title

   Cetuximab + Pemetrexed + Carboplatin/Cisplatin

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Protocol Violation

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         69

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         69

      type

      Received ≥1 Dose of Any Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         69

      type

      Completed 6 Cycles

   4. achievements

      1. comment

         All treated participants excluding those from a noncompliant study site.

         group Id

         FG000

         num Subjects

         58

      type

      Efficacy Population

   5. achievements

      1. group Id

         FG000

         num Subjects

         63

      type

      Received Carboplatin

   6. achievements

      1. group Id

         FG000

         num Subjects

         67

      type

      COMPLETED

   7. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice